You are here: Home About us Publications Articles


Consult the article list of PhinC' scientists.
Bioequivalence study of two Ibuprofen formulations administered intravenously in healthy male volunteers
Chassard D, Geneteau A, Gualano V, Brault M. Clin. Drug. Invest. 24(12): 739-747, 2004
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency
Chatelut E, Rostaing L, Gualano V, Vissac T, De Forni M, Ton-That H, Suc JM, Houin G, Canal P. Nephron. 66(2):157-61, 1994
Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers
de Forni M, Gualano V, Canal P, Martel P, Izar-Soum F, Chevreau C, Soulie P, Roche H, Bugat R. Bull Cancer 80(5):408-17, 1993 (French)
Comparative bioavailability study of two omeprazole formulations after single and repeated administrations
Duvauchelle T., Millérioux L., Gualano V. Evène E., Alcaïde A., Clin. Drug Investigation, 16, 141 –149, 1998
Population pharmacokinetics of ibuprofen enantiomers in very premature neonates
Grégoire N, Gualano V, Geneteau A, Millerioux L, Brault M, Mignot A, Roze J.C. J Clin Pharmacol. 44: 1114-24, 2004
Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose
Gregoire N, Hovsepian L, Gualano V, Evène E, Dufour G, Gendron A. Clin. Pharm; Ther., 81(3):401-5, 2007
Comparative bioavailability of two oral nimodipine formulations after administration to 24 healthy volunteers
Gualano V, Ntssikoussalabongui B, Mignot A, Duvauchelle T, Felices M, Guillaume M, Orlandini B, Holguin J, Alcaïde A.. Clin. Drug Investig. 17; 6: 475-82, 1999
Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers
Mignot A, Guillaume M, Brault M, Gualano V, Millerioux L, Gohler K, Stahlberg HJ. Chemotherapy. 48(3):116-21, 2002
High-performance liquid chromatographic determination of baclofen in human plasma
Millerioux L, Brault M, Gualano V, Mignot A. J Chromatogr A. 5;729(1-2):309-14, 1996
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study
Montastruc JL, Rascol O, Senard JM, Gualano V, Bagheri H, Houin G, Lees A, Rascol A. Clin. Neuropharmacol. , 14(5):432-7, 1991
Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion
Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G. Cancer Chemother Pharmacol.; 32(5): 379-84, 1993
Pharmacokinetics and tolerability of prulifloxacin after single oral administration
Picollo R, Brion N, Gualano V, Millerioux L, Marchetti M, Rosignoli MT, Dionisio P. Arzneimittelforschung; 53(3):201-5, 2003
Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men
Raynaud JP, Aumonier C, Gualano V, Betea D, Beckers A. J Steroid Biochem Mol Biol, 109(1-2):177-84, 2008
Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch
Santoro A, Rovati LC, Follet M, Setnikar I, Caplain H, Gualano V. Arzneimittelforschung;50(9):786-94, 2000
Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch
Santoro A, Rovati LC, Setnikar I, Caplain H, Gualano V. Arzneimittelforschung, 50(9): 779-85, 2000
Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch
Setnikar I, Rovati LC, Santoro A, Guillaume M, Mignot A, Renoux A, Gualano V. Arzneimittelforschung; 49(8): 708-15, 1999
Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix
Setnikar I, Rovati LC, Thebault JJ, Guillaume M, Mignot A, Renoux A, Gualano V. Arzneimittelforschung, 47(7):859-65, 1997
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors
Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C. Cancer Chemother Pharmacol. 1998
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149
Dirix L, Catimel G, Koier I, Provè A, Schrijvers D, Joossens E, De Bruijn E, Ardiet C, Evene E, Dumortier A, et al. Anticancer Drugs. 1995
A single-center, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (Zindaclin) and topical clindamycin lotion (Dalacin® T) in subjects with mild to moderate acne
Chassard D, Kanis R, Namour F, Evène E, Ntssikoussalabongui B, Schmitz V., J Dermatolog Treat, 17(3): 154-157, 2006
Bayesian estimation of pharmacokinetic parameters of etoposide
Evène E., Tranchand B., Chatelut E., Canal P., Ardiet C. Bulletin du Cancer, 84, 699 – 703, 1997 (French)
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F. J Antimicrob Chemother, 63(3):585-92, 2009
Pharmacokinetics of repaglinide in healthy Caucasian and Japanese Subjects
Thomsen M.S., Chassard D., Evène E., K.K. Nielsen, M. Jørgensen., J Clin Pharmacol, 43, 23-28, 2003
Filed under: